{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T22:34:52Z","timestamp":1789079692046,"version":"build-2803163510"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T00:00:00Z","timestamp":1719532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T00:00:00Z","timestamp":1719532800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002332","name":"Semmelweis University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002332","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Long-term data on ustekinumab in real-life Crohn\u2019s disease patients are still missing, though randomized controlled trials demonstrated it as a favorable therapeutic option. We aimed to evaluate ustekinumab's clinical efficacy, drug sustainability, and safety in a prospective, nationwide, multicenter Crohn\u2019s disease patient cohort with a three-year follow-up. Crohn\u2019s disease patients on ustekinumab treatment were consecutively enrolled from 9 Hungarian Inflammatory Bowel Disease centers between January 2019 and May 2020. Patient and disease characteristics, treatment history, clinical disease activity (Harvey Bradshaw Index (HBI)), biomarkers, and endoscopic activity (Simple Endoscopic Score for Crohn\u2019s Disease (SES-CD)) were collected for three-years\u2019 time. A total of 148 patients were included with an overall 48.9% of complex behavior of the Crohn\u2019s disease and 97.2% of previous anti-TNF exposure. The pre-induction remission rates were 12.2% (HBI), and 5.1% (SES-CD). Clinical remission rates (HBI) were 52.2%, 55.6%, and 50.9%, whereas criteria of an endoscopic remission were fulfilled in 14.3%, 27.5%, and 35.3% of the subjects at the end of the first, second, and third year, respectively. Dose intensification was high with 84.0% of the patients on an 8-weekly and 29.9% on a 4-weekly regimen at the end of year 3. Drug sustainability was 76.9% during the follow-up period with no serious adverse events observed. Ustekinumab in the long-term is an effective, sustainable, and safe therapeutic option for Crohn\u2019s disease patients with severe disease phenotype and high previous anti-TNF biological failure, requiring frequent dose intensifications.<\/jats:p>","DOI":"10.1038\/s41598-024-65987-1","type":"journal-article","created":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T09:22:23Z","timestamp":1719566543000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy, drug sustainability, and safety of ustekinumab treatment in Crohn\u2019s disease patients over three years"],"prefix":"10.1038","volume":"14","author":[{"given":"Laszlo J.","family":"Barkai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorant","family":"Gonczi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fruzsina","family":"Balogh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorottya","family":"Angyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaudia","family":"Farkas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadett","family":"Farkas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamas","family":"Molnar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamas","family":"Szamosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eszter","family":"Schafer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra A.","family":"Golovics","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Juhasz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arpad","family":"Patai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aron","family":"Vincze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Sarlos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Farkas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsolt","family":"Dubravcsik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamas G.","family":"Toth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajnal","family":"Szekely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pal","family":"Miheller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter L.","family":"Lakatos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akos","family":"Ilias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,28]]},"reference":[{"key":"65987_CR1","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41572-020-0156-2","volume":"6","author":"G Roda","year":"2020","unstructured":"Roda, G. et al. Crohn\u2019s disease. Nat. Rev. Dis. Prim. 6, 22 (2020).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"65987_CR2","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1093\/ecco-jcc\/jjz195","volume":"14","author":"JP Gisbert","year":"2020","unstructured":"Gisbert, J. P. & Chaparro, M. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients with Inflammatory Bowel Disease: From Basic Science to Clinical Practice. J. Crohn\u2019s Colitis 14, 694\u2013709 (2020).","journal-title":"J. Crohn\u2019s Colitis"},{"key":"65987_CR3","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1056\/NEJMoa033402","volume":"351","author":"PJ Mannon","year":"2004","unstructured":"Mannon, P. J. et al. Anti\u2013Interleukin-12 Antibody for Active Crohn\u2019s Disease. N. Engl. J. Med. 351, 2069\u20132079 (2004).","journal-title":"N. Engl. J. Med."},{"key":"65987_CR4","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","volume":"375","author":"BG Feagan","year":"2016","unstructured":"Feagan, B. G. et al. Ustekinumab as Induction and Maintenance Therapy for Crohn\u2019s Disease. N. Engl. J. Med. 375, 1946\u20131960 (2016).","journal-title":"N. Engl. J. Med."},{"key":"65987_CR5","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1053\/j.gastro.2018.06.035","volume":"155","author":"P Rutgeerts","year":"2018","unstructured":"Rutgeerts, P. et al. Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn\u2019s Disease. Gastroenterology 155, 1045\u20131058 (2018).","journal-title":"Gastroenterology"},{"key":"65987_CR6","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.dld.2021.07.008","volume":"54","author":"L Gonczi","year":"2022","unstructured":"Gonczi, L. et al. Clinical efficacy, drug sustainability and serum drug levels in Crohn\u2019s disease patients treated with ustekinumab\u2014A prospective, multicenter cohort from Hungary. Dig. Liver Dis. 54, 207\u2013213 (2022).","journal-title":"Dig. Liver Dis."},{"key":"65987_CR7","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1136\/gut.2005.082909","volume":"55","author":"J Satsangi","year":"2006","unstructured":"Satsangi, J., Silverberg, M. S., Vermeire, S. & Colombel, J. F. The Montreal classification of inflammatory bowel disease: Controversies, consensus, and implications. Gut 55, 749\u2013753 (2006).","journal-title":"Gut"},{"key":"65987_CR8","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/0016-5085(79)90384-6","volume":"77","author":"WR Best","year":"1979","unstructured":"Best, W. R., Becktel, J. M. & Singleton, J. W. Rederived values of the eight coefficients of the Crohn\u2019s disease activity index (CDAI). Gastroenterology 77, 843\u2013846 (1979).","journal-title":"Gastroenterology"},{"key":"65987_CR9","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.cgh.2010.01.001","volume":"8","author":"S Vermeire","year":"2010","unstructured":"Vermeire, S., Schreiber, S., Sandborn, W. J., Dubois, C. & Rutgeerts, P. Correlation Between the Crohn\u2019s Disease Activity and Harvey-Bradshaw Indices in Assessing Crohn\u2019s Disease Severity. Clin. Gastroenterol. Hepatol. 8, 357\u2013363 (2010).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"65987_CR10","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0016-5107(04)01878-4","volume":"60","author":"M Daperno","year":"2004","unstructured":"Daperno, M. et al. Development and validation of a new, simplified endoscopic activity score for Crohn\u2019s disease: The SES-CD. Gastrointest Endosc. 60, 505\u2013512 (2004).","journal-title":"Gastrointest Endosc."},{"key":"65987_CR11","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/ecco-jcc\/jjz119","volume":"14","author":"VBC Biemans","year":"2020","unstructured":"Biemans, V. B. C. et al. Ustekinumab for Crohn\u2019s Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study. J. Crohn\u2019s Colitis 14, 33\u201345 (2020).","journal-title":"J. Crohn\u2019s Colitis"},{"key":"65987_CR12","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1093\/ecco-jcc\/jjab081","volume":"15","author":"T Straatmijer","year":"2021","unstructured":"Straatmijer, T. et al. Ustekinuma b for Crohn\u2019s Disease: Two-year results of the initiative on Crohn and colitis (ICC) registry, a nationwide prospective observational cohort study. J. Crohn\u2019s Colitis 15, 1920\u20131930 (2021).","journal-title":"J. Crohn\u2019s Colitis"},{"key":"65987_CR13","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/j.cgh.2017.03.032","volume":"15","author":"R Battat","year":"2017","unstructured":"Battat, R. et al. Association between Ustekinumab trough concentrations and clinical, biomarker, and endoscopic outcomes in patients with Crohn\u2019s disease. Clin. Gastroenterol. Hepatol. 15, 1427-1434.e2 (2017).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"65987_CR14","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1177\/2050640620902956","volume":"8","author":"A Bar-Gil Shitrit","year":"2020","unstructured":"Bar-Gil Shitrit, A. et al. Safety and effectiveness of ustekinumab for induction of remission in patients with Crohn\u2019s disease: A multicenter Israeli study. United Eur. Gastroenterol. J. 8, 418\u2013424 (2020).","journal-title":"United Eur. Gastroenterol. J."},{"key":"65987_CR15","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1002\/jgh3.12502","volume":"5","author":"A Viola","year":"2021","unstructured":"Viola, A. et al. Ustekinumab in Crohn\u2019s disease: Real-world outcomes from the Sicilian network for inflammatory bowel diseases. JGH Open 5, 364\u2013370 (2021).","journal-title":"JGH Open"},{"key":"65987_CR16","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/apt.14794","volume":"48","author":"WJ Sandborn","year":"2018","unstructured":"Sandborn, W. J. et al. Long-term efficacy and safety of ustekinumab for Crohn\u2019s disease through the second year of therapy. Aliment Pharmacol. Ther. 48, 65\u201377 (2018).","journal-title":"Aliment Pharmacol. Ther."},{"key":"65987_CR17","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1093\/ecco-jcc\/jjz110","volume":"14","author":"SB Hanauer","year":"2020","unstructured":"Hanauer, S. B. et al. IM-UNITI: Three-year efficacy, safety, and immunogenicity of ustekinumab treatment of Crohn\u2019s disease. J. Crohn\u2019s Colitis 14, 23\u201332 (2020).","journal-title":"J. Crohn\u2019s Colitis"},{"key":"65987_CR18","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/MEG.0000000000002506","volume":"35","author":"PWA Thomas","year":"2023","unstructured":"Thomas, P. W. A. et al. Long-term effectiveness and safety of ustekinumab in Crohn\u2019s disease: A prospective cohort study. Eur. J. Gastroenterol. Hepatol. 35, 261\u2013269 (2023).","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"65987_CR19","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10620-022-07501-z","volume":"68","author":"A Forss","year":"2023","unstructured":"Forss, A. et al. Ustekinumab Is Associated with Real-World Long-Term Effectiveness and Improved Health-Related Quality of Life in Crohn\u2019s Disease. Dig. Dis. Sci. 68, 65\u201376 (2023).","journal-title":"Dig. Dis. Sci."},{"key":"65987_CR20","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1111\/apt.14487","volume":"47","author":"P Wils","year":"2018","unstructured":"Wils, P. et al. Long-term efficacy and safety of ustekinumab in 122 refractory Crohn\u2019s disease patients: A multicentre experience. Aliment. Pharmacol. Ther. 47, 588\u2013595 (2018).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"65987_CR21","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1097\/MIB.0000000000001074","volume":"23","author":"C Ma","year":"2017","unstructured":"Ma, C. et al. Long-term maintenance of clinical, endoscopic, and radiographic response to Ustekinumab in moderate-to-severe Crohn\u2019s disease: Real-world experience from a multicenter cohort study. Inflamm. Bowel. Dis. 23, 833\u2013839 (2017).","journal-title":"Inflamm. Bowel. Dis."},{"key":"65987_CR22","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1097\/MEG.0000000000001831","volume":"32","author":"CG Af Bj\u00f6rkesten","year":"2020","unstructured":"Af Bj\u00f6rkesten, C. G. et al. Objectively assessed disease activity and drug persistence during ustekinumab treatment in a nationwide real-world Crohn\u2019s disease cohort. Eur. J. Gastroenterol. Hepatol. 32, 1507\u20131513 (2020).","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"65987_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11216481","author":"JMF Chebli","year":"2022","unstructured":"Chebli, J. M. F. et al. Effectiveness and Safety of Ustekinumab for Moderate to Severely Active Crohn\u2019s Disease: Results from an Early Access Program in Brazil. J. Clin. Med. https:\/\/doi.org\/10.3390\/jcm11216481 (2022).","journal-title":"J. Clin. Med."},{"key":"65987_CR24","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/nbt1303","volume":"25","author":"G Shankar","year":"2007","unstructured":"Shankar, G., Pendley, C. & Stein, K. E. A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. Nat. Biotechnol. 25, 555\u2013561 (2007).","journal-title":"Nat. Biotechnol."},{"key":"65987_CR25","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s40259-017-0231-8","volume":"31","author":"V Strand","year":"2017","unstructured":"Strand, V. et al. Immunogenicity of biologics in chronic inflammatory diseases: A systematic review. BioDrugs 31, 299\u2013316 (2017).","journal-title":"BioDrugs"},{"key":"65987_CR26","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1007\/s10620-020-06344-w","volume":"66","author":"VS Rolston","year":"2021","unstructured":"Rolston, V. S. et al. Ustekinumab does not increase risk of adverse events: A meta-analysis of randomized controlled trials. Dig. Dis. Sci. 66, 1631\u20131638 (2021).","journal-title":"Dig. Dis. Sci."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-65987-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-65987-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-65987-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T09:26:35Z","timestamp":1719566795000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-65987-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,28]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["65987"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-65987-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,28]]},"assertion":[{"value":"12 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"LJB, LG, FB, DA, BF, TS, ES, PAG, MJ, AP, AV, PS, AF, ZD, TGT, HSz, PM, PLL, and AI declare no conflict of interest. Klaudia Farkas has received speaker\u2019s honoraria from AbbVie, Janssen, Ferring, Takeda, Pfizer, Bristol-Myers Squibb and Goodwill Pharma. Tam\u00e1s Moln\u00e1r has received speaker\u2019s honoraria from MSD, AbbVie, Egis, Goodwill Pharma, Takeda, Pfizer, Janssen, Sandoz, MundiPharma, Phytotec, Roche, Fresenius, Bristol-Myers Squibb, Lilly and Teva.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14909"}}